Cargando…

Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity

OBJECTIVES: The objective of this study was to evaluate the effect and safety of trigonal injection of botulinum toxin A (BTX-A) for patients with neurological detrusor overactivity (NDO) with incontinence. METHODS: A prospective, multicenter, single-blind and randomized controlled trial was conduct...

Descripción completa

Detalles Bibliográficos
Autores principales: Hui, C, Keji, X, Chonghe, J, Ping, T, Rubiao, O, Jianweng, Z, Xiangrong, D, Liling, Z, Maping, H, Qingqing, L, Qiuling, L, Jiebing, H, Tanghai, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399134/
https://www.ncbi.nlm.nih.gov/pubmed/26261074
http://dx.doi.org/10.1038/sc.2015.143
_version_ 1783230575543320576
author Hui, C
Keji, X
Chonghe, J
Ping, T
Rubiao, O
Jianweng, Z
Xiangrong, D
Liling, Z
Maping, H
Qingqing, L
Qiuling, L
Jiebing, H
Tanghai, H
author_facet Hui, C
Keji, X
Chonghe, J
Ping, T
Rubiao, O
Jianweng, Z
Xiangrong, D
Liling, Z
Maping, H
Qingqing, L
Qiuling, L
Jiebing, H
Tanghai, H
author_sort Hui, C
collection PubMed
description OBJECTIVES: The objective of this study was to evaluate the effect and safety of trigonal injection of botulinum toxin A (BTX-A) for patients with neurological detrusor overactivity (NDO) with incontinence. METHODS: A prospective, multicenter, single-blind and randomized controlled trial was conducted between June 2011 and June 2014. Spinal cord injury patients with urinary incontinence secondary to NDO overactivity were recruited. At a 1:1 ratio, patients randomly received 200 U BTX-A intradetrusor injections excluding the trigone (the control group) or 160 U intradetrusor and 40 U intratrigonal injections (the experimental group). Patients were evaluated at baseline and at 4 and 12 weeks after injection. The efficacy and safety outcomes included Incontinence-Specific-Quality-of-Life Instrument (I-QoL), voiding volume, urinary incontinence episodes, complete dryness, maximum detrusor pressure (P(detmax)) and volume at first involuntary detrusor contraction (V(FIDC)). Vesicoureteral reflux (VUR) and other adverse events were recorded. RESULTS: Ninety-six patients were recruited and 91 of them completed the trial. Among the 91 patients, 47 were randomized to the experimental group and 44 to the control group. There were no significant differences in baseline evaluation items (gender, age, duration of spinal cord injury, level of neurological injury, AIS (the American Social Injury Association) scores) between the two groups. At 12 weeks, the improvement was significantly better in the experimental group compared with that in the control group for I-QoL (26.01 vs 18.75, P=0.01), mean urinary incontinence episodes (−5.22 vs −4.68 per day, P=0.01), complete dryness (13 vs 5, P=0.03), mean voiding volume (159.72 vs 139.07 ml, P=0.02), P(detmax) (−33.34 vs −28.02 cmH(2)O, P=0.04) and VFIDC (106.81 vs 97.86 ml, P=0.02), duration of first detrusor contraction (−41.54 vs −18.65 s, P=0.03) and the number of patients with detrusor contraction (−20 vs −9, P=0.02). In both the groups, no patients developed VUR. CONCLUSIONS: BTX-A intradetrusor and intratrigonal injections are more effective compared with those excluding the trigone for patients with NDO with incontinence. Intratrigonal injections do not induce VUR.
format Online
Article
Text
id pubmed-5399134
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-53991342017-05-09 Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity Hui, C Keji, X Chonghe, J Ping, T Rubiao, O Jianweng, Z Xiangrong, D Liling, Z Maping, H Qingqing, L Qiuling, L Jiebing, H Tanghai, H Spinal Cord Original Article OBJECTIVES: The objective of this study was to evaluate the effect and safety of trigonal injection of botulinum toxin A (BTX-A) for patients with neurological detrusor overactivity (NDO) with incontinence. METHODS: A prospective, multicenter, single-blind and randomized controlled trial was conducted between June 2011 and June 2014. Spinal cord injury patients with urinary incontinence secondary to NDO overactivity were recruited. At a 1:1 ratio, patients randomly received 200 U BTX-A intradetrusor injections excluding the trigone (the control group) or 160 U intradetrusor and 40 U intratrigonal injections (the experimental group). Patients were evaluated at baseline and at 4 and 12 weeks after injection. The efficacy and safety outcomes included Incontinence-Specific-Quality-of-Life Instrument (I-QoL), voiding volume, urinary incontinence episodes, complete dryness, maximum detrusor pressure (P(detmax)) and volume at first involuntary detrusor contraction (V(FIDC)). Vesicoureteral reflux (VUR) and other adverse events were recorded. RESULTS: Ninety-six patients were recruited and 91 of them completed the trial. Among the 91 patients, 47 were randomized to the experimental group and 44 to the control group. There were no significant differences in baseline evaluation items (gender, age, duration of spinal cord injury, level of neurological injury, AIS (the American Social Injury Association) scores) between the two groups. At 12 weeks, the improvement was significantly better in the experimental group compared with that in the control group for I-QoL (26.01 vs 18.75, P=0.01), mean urinary incontinence episodes (−5.22 vs −4.68 per day, P=0.01), complete dryness (13 vs 5, P=0.03), mean voiding volume (159.72 vs 139.07 ml, P=0.02), P(detmax) (−33.34 vs −28.02 cmH(2)O, P=0.04) and VFIDC (106.81 vs 97.86 ml, P=0.02), duration of first detrusor contraction (−41.54 vs −18.65 s, P=0.03) and the number of patients with detrusor contraction (−20 vs −9, P=0.02). In both the groups, no patients developed VUR. CONCLUSIONS: BTX-A intradetrusor and intratrigonal injections are more effective compared with those excluding the trigone for patients with NDO with incontinence. Intratrigonal injections do not induce VUR. Nature Publishing Group 2016-01 2015-08-11 /pmc/articles/PMC5399134/ /pubmed/26261074 http://dx.doi.org/10.1038/sc.2015.143 Text en Copyright © 2016 International Spinal Cord Society http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
spellingShingle Original Article
Hui, C
Keji, X
Chonghe, J
Ping, T
Rubiao, O
Jianweng, Z
Xiangrong, D
Liling, Z
Maping, H
Qingqing, L
Qiuling, L
Jiebing, H
Tanghai, H
Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity
title Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity
title_full Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity
title_fullStr Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity
title_full_unstemmed Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity
title_short Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity
title_sort combined detrusor-trigone btx-a injections for urinary incontinence secondary to neurogenic detrusor overactivity
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5399134/
https://www.ncbi.nlm.nih.gov/pubmed/26261074
http://dx.doi.org/10.1038/sc.2015.143
work_keys_str_mv AT huic combineddetrusortrigonebtxainjectionsforurinaryincontinencesecondarytoneurogenicdetrusoroveractivity
AT kejix combineddetrusortrigonebtxainjectionsforurinaryincontinencesecondarytoneurogenicdetrusoroveractivity
AT chonghej combineddetrusortrigonebtxainjectionsforurinaryincontinencesecondarytoneurogenicdetrusoroveractivity
AT pingt combineddetrusortrigonebtxainjectionsforurinaryincontinencesecondarytoneurogenicdetrusoroveractivity
AT rubiaoo combineddetrusortrigonebtxainjectionsforurinaryincontinencesecondarytoneurogenicdetrusoroveractivity
AT jianwengz combineddetrusortrigonebtxainjectionsforurinaryincontinencesecondarytoneurogenicdetrusoroveractivity
AT xiangrongd combineddetrusortrigonebtxainjectionsforurinaryincontinencesecondarytoneurogenicdetrusoroveractivity
AT lilingz combineddetrusortrigonebtxainjectionsforurinaryincontinencesecondarytoneurogenicdetrusoroveractivity
AT mapingh combineddetrusortrigonebtxainjectionsforurinaryincontinencesecondarytoneurogenicdetrusoroveractivity
AT qingqingl combineddetrusortrigonebtxainjectionsforurinaryincontinencesecondarytoneurogenicdetrusoroveractivity
AT qiulingl combineddetrusortrigonebtxainjectionsforurinaryincontinencesecondarytoneurogenicdetrusoroveractivity
AT jiebingh combineddetrusortrigonebtxainjectionsforurinaryincontinencesecondarytoneurogenicdetrusoroveractivity
AT tanghaih combineddetrusortrigonebtxainjectionsforurinaryincontinencesecondarytoneurogenicdetrusoroveractivity